Diligence memo · auto-generated · as of July 3, 2026
TCG Fluent Pharma Investors LP
TCG Fluent Pharma Investors LP looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
TCG Fluent Pharma Investors LP operates in Pharmaceuticals, based in NEWPORT BEACH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TCG Fluent Pharma Investors LP has raised $6.1M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.5M on 2017-02-16.
Most recent recorded round closed around 2019-07-19.
Valuation (modeled)modeled
Provath models TCG Fluent Pharma Investors LP at approximately $19M (range $716K–$105M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.13× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 7.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 8.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 46% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 27% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.